PMC:7195088 / 6002-6406 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"156","span":{"begin":139,"end":147},"obj":"Species"},{"id":"192","span":{"begin":87,"end":97},"obj":"Chemical"},{"id":"193","span":{"begin":307,"end":318},"obj":"Chemical"},{"id":"194","span":{"begin":323,"end":333},"obj":"Chemical"},{"id":"216","span":{"begin":130,"end":138},"obj":"Disease"}],"attributes":[{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"Tax:9606"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:C000606551"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:C462182"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:C086979"},{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"til results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature. Pending high-level supporting evidence, favipiravir and umifenovir should not be provided an outside RCT, at least in those countries whe"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":130,"end":138},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"til results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature. Pending high-level supporting evidence, favipiravir and umifenovir should not be provided an outside RCT, at least in those countries whe"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21","span":{"begin":87,"end":97},"obj":"Chemical"},{"id":"T22","span":{"begin":307,"end":318},"obj":"Chemical"},{"id":"T23","span":{"begin":323,"end":333},"obj":"Chemical"}],"attributes":[{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"}],"text":"til results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature. Pending high-level supporting evidence, favipiravir and umifenovir should not be provided an outside RCT, at least in those countries whe"}

{"project":"LitCovid-sentences","denotations":[{"id":"T43","span":{"begin":44,"end":266},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"til results of dedicated RCT are available. Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature. Pending high-level supporting evidence, favipiravir and umifenovir should not be provided an outside RCT, at least in those countries whe"}